TRENDING:

NCPE Recommends Conditional Access for Omeprazole
Stratipath And Roche Collaborate To Expand Access To Ai...
A. Menarini Diagnostics and Nucleix Form Strategic Part...
  • Home
  • Media
  • Company
Synopulse.com
  • News
  • Industry Trends
    • Pricing & Market Access
    • Earnings Report
    • Market Pulse
    • Speciality
      • Neurology
      • Orthopaedics
      • Oncology
      • Cardiometabolic
      • Pediatrics
    • Dealstreet
    • Litigation, Law & Policy
    • MedTech
  • Regulatory
    • FDA Updates
    • EMA Updates
    • Device Approvals
    • Global Compliance
  • Monthly Standout
    • Monthly Insight’s
    • GreenLight Report
  • Special Reports
    • Synopulse 360
    • Synopulse Insights
    • RWE Lens
    • White Paper
    • Case Study
  • Magazine
    • Pulse Prime
    • Pulse of the Month
  • Disease Spotlight
  • Summits
  • Podcasts

Select Page

EQT to Acquire GeBBS Healthcare Solutions

Sep 10, 2024 | Dealstreet, News

EQT Private Capital Asia has announced its agreement to acquire a controlling interest in GeBBS Healthcare Solutions from ChrysCapital. GeBBS specializes in revenue cycle management, health information management (HIM), and medical billing services, helping U.S.-based healthcare providers improve their financial performance through optimized revenue cycle processes and accurate coding and billing practices.

Founded in 2005, GeBBS has a global presence with 13,000 employees across the U.S., India, the Dominican Republic, and the Philippines. The company has built strong relationships with a diverse customer base, including hospitals, physician groups, and other healthcare firms.

EQT’s acquisition aims to support GeBBS in its next phase of growth, including expansion into new customer segments, enhancing in-house technology capabilities, and pursuing further mergers and acquisitions. EQT’s investment will leverage its extensive experience in healthcare technology and its value-creation playbook to drive GeBBS’ growth.

Hari Gopalakrishnan from EQT noted the alignment between GeBBS’ growth ambitions and EQT’s experience in creating long-term value. GeBBS’ CEO, Dr. Milind Godbole, welcomed EQT’s expertise, believing it will help propel the company to new heights. ChrysCapital, which has overseen GeBBS’ growth and expansion, is stepping away after facilitating significant organic growth and strategic acquisitions.

The transaction is expected to close in Q4 2024, with EQT being advised by Ropes & Gray, JSA Law, Deloitte Touche Tohmatsu Limited, and PricewaterhouseCooper. The selling shareholders were advised by Jefferies and Avendus. For more information, contact EQT Press Office at press@eqtpartners.com.

Share:

PreviousA. Menarini Diagnostics and Nucleix Form Strategic Partnership for Non-Invasive Bladder Cancer Test in Europe
NextKalsi Insurance Partners with Integrity to Provide Enhanced Insurance Solutions to Underserved Communities
Synopulse Weekly

Synopulse Weekly: Top Deals, FDA Moves & Pricing Insights

Read Now
  • Cardiometabolic
  • Dealstreet
  • Device Approvals
  • EMA Updates
  • FDA Updates
  • Litigation, Law & Policy
  • MedTech
  • Monthly Insight's
  • Neurology
  • News
  • Oncology
  • Orthopaedics
  • Pediatrics
  • Pricing & Market Access
  • Regulatory
  • July 2025
  • June 2025
  • February 2025
  • January 2025
  • October 2024
  • September 2024

© 2025 Axowit | All Rights Reserved